While the exact mechanisms of DPPIV’s involvement in SARS-CoV-2 infection are still being explored, the existing evidence suggests that targeting DPPIV may reduce the risk of long-term cerebrovascular complications, including stroke and cognitive decline, in post-COVID-19 patients. This evidence concerns the gene DPP4 and COVID-19.